Commercial
Advanced Search
  
  
  
  
  
  
  
  
  
  
MPattachmentdataPub
42f58b0d-b1cf-4935-8038-62c796bb7741.aspx
  
08.01.40fLanreotide(Somatuline®Depot)08.01.40fPharmacy (08)Lanreotide (Somatuline® Depot)42f58b0d-b1cf-4935-8038-62c796bb77416099Lanreotide (Somatuline® Depot)08.01.40
{"6100": {"Id":6100,"MPAttachmentLetter":"A","Title":"ICD-10 CODES AND NARRATIVES","MPPolicyAttachmentInternalSourceId":8170,"PolicyAttachmentPageName":"ccc8b641-3305-4c0d-ab2e-0fa2e4145f8f"},}
d5b37eea-94fa-49a6-aeb5-ec0985f7bacd.aspx
  
11.06.10aLaparoscopic,Percutaneous,andTranscervicalTechniquesforUterineFibroidMyolysis11.06.10aSurgery (11)Laparoscopic, Percutaneous, and Transcervical Techniques for Uterine Fibroid Myolysisd5b37eea-94fa-49a6-aeb5-ec0985f7bacd5974Laparoscopic, Percutaneous, and Transcervical Techniques for Uterine Fibroid Myolysis11.06.10
a9305dbb-78ab-4c4a-888e-280db458b862.aspx
  
11.08.03mLipectomyandLiposuction11.08.03mSurgery (11)Lipectomy and Liposuctiona9305dbb-78ab-4c4a-888e-280db458b8625702Lipectomy and Liposuction11.08.03
a3a2c530-9cbb-478e-8f5d-eb80dcba042f.aspx
  
08.00.59cLoncastuximabtesirine-lpyl(Zynlonta®)08.00.59cPharmacy (08)Loncastuximab tesirine-lpyl (Zynlonta®)a3a2c530-9cbb-478e-8f5d-eb80dcba042f5772Loncastuximab tesirine-lpyl (Zynlonta®)08.00.59
163a3a21-e0af-4449-bfe4-f0130f43743d.aspx
  
05.00.59mLowerLimbProstheses05.00.59mDME (05)Lower Limb Prostheses163a3a21-e0af-4449-bfe4-f0130f43743d5960Lower Limb Prostheses05.00.59
{"5961": {"Id":5961,"MPAttachmentLetter":"A","Title":"HCPCS Level II Code Number(s) and Narrative(s)","MPPolicyAttachmentInternalSourceId":8226,"PolicyAttachmentPageName":"80458a18-d7b4-46c3-9de2-da425dc76567"},}
4e39b453-4a5b-4a91-885a-e7b7ab9d5eb9.aspx
  
09.00.31dLowOsmolarContrastAgents09.00.31dRadiology (09)Low Osmolar Contrast Agents4e39b453-4a5b-4a91-885a-e7b7ab9d5eb95061Low Osmolar Contrast Agents09.00.31
22d86ae7-c1e7-42f8-bcd0-706e6eb293e8.aspx
  
08.01.74Lumasiran(Oxlumo™)08.01.74Pharmacy (08)Lumasiran (Oxlumo™)22d86ae7-c1e7-42f8-bcd0-706e6eb293e85891Lumasiran (Oxlumo™)08.01.74
e5b6f045-f809-4c00-bb3c-f544d906da84.aspx
  
08.01.67cLurbinectedin(Zepzelca®)08.01.67cPharmacy (08)Lurbinectedin (Zepzelca®)e5b6f045-f809-4c00-bb3c-f544d906da845290Lurbinectedin (Zepzelca®)08.01.67
0f67d2dd-b927-4f7a-bbad-842856794d67.aspx
  
08.00.10cLuspatercept–aamt(Reblozyl®)08.00.10cPharmacy (08)Luspatercept–aamt (Reblozyl®)0f67d2dd-b927-4f7a-bbad-842856794d675316Luspatercept–aamt (Reblozyl®)08.00.10
008dc90f-ae42-4690-a94b-59b4e4d44195.aspx
  
08.01.57Lutathera®(LutetiumLu177Dotatate)(IndependenceAdministrators)08.01.57Pharmacy (08)Lutathera® (Lutetium Lu 177 Dotatate) (Independence Administrators)008dc90f-ae42-4690-a94b-59b4e4d441955825Lutathera® (Lutetium Lu 177 Dotatate) (Independence Administrators)08.01.57
ea8b568d-9904-4482-bfac-b0b24d4acb00.aspx
  
06.02.01kLymeDisease:DiagnosisandIntravenous(IV)AntibioticTherapy06.02.01kPathology and Laboratory (06)Lyme Disease: Diagnosis and Intravenous (IV) Antibiotic Therapyea8b568d-9904-4482-bfac-b0b24d4acb005831Lyme Disease: Diagnosis and Intravenous (IV) Antibiotic Therapy06.02.01
7a62ee9d-35b3-428e-9f4a-0878c125066e.aspx
  
09.00.45kMagneticResonanceImaging(MRI)ContrastAgents09.00.45kRadiology (09)Magnetic Resonance Imaging (MRI) Contrast Agents7a62ee9d-35b3-428e-9f4a-0878c125066e5778Magnetic Resonance Imaging (MRI) Contrast Agents09.00.45
4ad1cfa7-090d-4e50-901e-fefce9cc8ebe.aspx
  
11.06.06gMagneticResonanceImaging(MRI)-GuidedFocusedUltrasoundAblation11.06.06gSurgery (11)Magnetic Resonance Imaging (MRI)-Guided Focused Ultrasound Ablation4ad1cfa7-090d-4e50-901e-fefce9cc8ebe5479Magnetic Resonance Imaging (MRI)-Guided Focused Ultrasound Ablation11.06.06
df76937c-c78f-4b13-afb1-eedc0c58be4d.aspx
  
08.01.37cMaintenanceTreatmentofOpioidorAlcoholUseDisorder08.01.37cPharmacy (08)Maintenance Treatment of Opioid or Alcohol Use Disorder df76937c-c78f-4b13-afb1-eedc0c58be4d5183Maintenance Treatment of Opioid or Alcohol Use Disorder 08.01.37
{"5184": {"Id":5184,"MPAttachmentLetter":"A","Title":"ICD10 Codes","MPPolicyAttachmentInternalSourceId":7188,"PolicyAttachmentPageName":"6e6e1abb-fabe-43d6-b5ec-b082eab6e073"},}
8976551b-e116-46a1-9813-0c82b43e743d.aspx
  
11.14.24bManipulationUnderAnesthesia11.14.24bSurgery (11)Manipulation Under Anesthesia8976551b-e116-46a1-9813-0c82b43e743d6114Manipulation Under Anesthesia11.14.24
aad25590-3c6e-4393-abd4-fdc897f4e357.aspx
  
05.00.12jManualWheelchairs05.00.12jDME (05)Manual Wheelchairsaad25590-3c6e-4393-abd4-fdc897f4e3575200Manual Wheelchairs05.00.12
{"5201": {"Id":5201,"MPAttachmentLetter":"A","Title":"HCPCS Codes for Manual Wheelchairs","MPPolicyAttachmentInternalSourceId":7194,"PolicyAttachmentPageName":"cd002ff1-aa24-44ca-b7b7-f87e169ebb66"},}
c6110f54-8aba-43e3-ad1b-8f665b4fb398.aspx
  
08.01.75cMargetuximab-cmkb(Margenza)08.01.75cPharmacy (08)Margetuximab-cmkb (Margenza)c6110f54-8aba-43e3-ad1b-8f665b4fb3985375Margetuximab-cmkb (Margenza)08.01.75
{"5376": {"Id":5376,"MPAttachmentLetter":"A","Title":"ICD 10 Codes","MPPolicyAttachmentInternalSourceId":7399,"PolicyAttachmentPageName":"7d39c0cb-2804-4651-85bb-c3e63b0631bb"},}
e2f8796c-a9d5-4675-8532-35b82f7ebbd4.aspx
  
00.01.48dMarijuanaforMedicalUse00.01.48dAdministrative (00)Marijuana for Medical Usee2f8796c-a9d5-4675-8532-35b82f7ebbd45488Marijuana for Medical Use00.01.48
235e6ba3-5d6f-4355-a830-bbb600937b1b.aspx
  
07.11.02fMeasurementofExhaledNitricOxideandBreathCondensateintheDiagnosisandManagementofAsthmaandOtherRespiratoryDisorders07.11.02fMedicine (07)Measurement of Exhaled Nitric Oxide and Breath Condensate in the Diagnosis and Management of Asthma and Other Respiratory Disorders235e6ba3-5d6f-4355-a830-bbb600937b1b5332Measurement of Exhaled Nitric Oxide and Breath Condensate in the Diagnosis and Management of Asthma and Other Respiratory Disorders07.11.02
7f27ada8-d669-4ec3-b68f-290aef45b5c6.aspx
  
06.02.39dMeasurementofSerumAntibodiestoandMeasurementofSerumLevelsofBiologics06.02.39dPathology and Laboratory (06)Measurement of Serum Antibodies to and Measurement of Serum Levels of Biologics7f27ada8-d669-4ec3-b68f-290aef45b5c65331Measurement of Serum Antibodies to and Measurement of Serum Levels of Biologics06.02.39
b7fe7e35-7711-4fdd-82eb-f752fad6f821.aspx
  
05.00.70cMechanicalStretchingDevicesfortheTreatmentofJointStiffnessorContractures05.00.70cDME (05)Mechanical Stretching Devices for the Treatment of Joint Stiffness or Contracturesb7fe7e35-7711-4fdd-82eb-f752fad6f8215296Mechanical Stretching Devices for the Treatment of Joint Stiffness or Contractures05.00.70
1950a315-92b0-495c-b23e-461bb1148962.aspx
  
07.08.03iMedicalandSurgicalTreatmentofTemporomandibularJointDisorder07.08.03iMedicine (07)Medical and Surgical Treatment of Temporomandibular Joint Disorder1950a315-92b0-495c-b23e-461bb11489626067Medical and Surgical Treatment of Temporomandibular Joint Disorder07.08.03
b9237846-fbc8-493b-a3ec-ae86e6347eed.aspx
  
07.03.03hMedicalEvaluationandManagementforAttention-DeficitHyperactivityDisorder(ADHD)07.03.03hMedicine (07)Medical Evaluation and Management for Attention-Deficit Hyperactivity Disorder (ADHD)b9237846-fbc8-493b-a3ec-ae86e6347eed4694Medical Evaluation and Management for Attention-Deficit Hyperactivity Disorder (ADHD)07.03.03
7553070b-0399-418f-867a-beedc8771d1e.aspx
  
12.01.02bMedicalNecessity12.01.02bMiscellaneous (12)Medical Necessity7553070b-0399-418f-867a-beedc8771d1e5902Medical Necessity12.01.02
ab9b0f50-63ad-4931-9745-9c521bfc4b02.aspx
  
11.14.03hMeniscalAllograftTransplantationandMeniscalImplants(IndependenceAdministrators)11.14.03hSurgery (11)Meniscal Allograft Transplantation and Meniscal Implants (Independence Administrators)ab9b0f50-63ad-4931-9745-9c521bfc4b025164Meniscal Allograft Transplantation and Meniscal Implants (Independence Administrators)11.14.03
{"5165": {"Id":5165,"MPAttachmentLetter":"A","Title":"ICD-10-CM codes","MPPolicyAttachmentInternalSourceId":7283,"PolicyAttachmentPageName":"782f8d54-d2fa-430c-81d5-d6a595b24631"},}
86e5fd7e-aad4-4118-b434-e2a0fb9fc603.aspx
  
11.14.01hMentoplastyorGenioplasty11.14.01hSurgery (11)Mentoplasty or Genioplasty86e5fd7e-aad4-4118-b434-e2a0fb9fc6035634Mentoplasty or Genioplasty11.14.01
bc4c5498-29e7-4bd2-9c0f-299e58e5fede.aspx
  
11.14.21iMicroprocessor-ControlledProsthesesforLower-ExtremityAmputees11.14.21iSurgery (11)Microprocessor-Controlled Prostheses for Lower-Extremity Amputeesbc4c5498-29e7-4bd2-9c0f-299e58e5fede3078Microprocessor-Controlled Prostheses for Lower-Extremity Amputees11.14.21
29e06d23-ef41-43a6-9ff1-03d2c121acb2.aspx
  
11.15.24aMigraineDeactivationSurgery11.15.24aSurgery (11)Migraine Deactivation Surgery29e06d23-ef41-43a6-9ff1-03d2c121acb25259Migraine Deactivation Surgery11.15.24
5a679ac6-c091-4f81-8384-68b9b275f8a1.aspx
  
08.02.01aMirvetuximabsoravtansine-gynx(ElahereTM)08.02.01aPharmacy (08)Mirvetuximab soravtansine-gynx (Elahere TM)5a679ac6-c091-4f81-8384-68b9b275f8a15426Mirvetuximab soravtansine-gynx (Elahere TM)08.02.01
de9e9c47-3bb4-480c-af79-6d57825dc617.aspx
  
03.00.15pModifier24:UnrelatedEvaluationandManagementServicebytheSamePhysicianorOtherQualifiedHealthCareProfessionalDuringaPostoperativePeriod03.00.15pClinical Logic (03)Modifier 24: Unrelated Evaluation and Management Service by the Same Physician or Other Qualified Health Care Professional During a Postoperative Periodde9e9c47-3bb4-480c-af79-6d57825dc6175064Modifier 24: Unrelated Evaluation and Management Service by the Same Physician or Other Qualified Health Care Professional During a Postoperative Period03.00.15
8f72283d-b853-4bdd-b3ad-a5497a267082.aspx
  
03.00.06zModifier25:Significant,SeparatelyIdentifiableEvaluationandManagementServicebytheSamePhysicianorOtherQualifiedHealthCareProfessionalontheSameDayoftheProcedureorOtherService03.00.06zClinical Logic (03)Modifier 25: Significant, Separately Identifiable Evaluation and Management Service by the Same Physician or Other Qualified Health Care Professional on the Same Day of the Procedure or Other Service8f72283d-b853-4bdd-b3ad-a5497a2670825997Modifier 25: Significant, Separately Identifiable Evaluation and Management Service by the Same Physician or Other Qualified Health Care Professional on the Same Day of the Procedure or Other Service03.00.06
{"5998": {"Id":5998,"MPAttachmentLetter":"B","Title":"Problem-focused E&M Codes appended with modifier 25 should be reimbursed at 50% of the applicable fee schedule amount when submitted on the same date of service by the same professional provider or other qualified health care provider, as a preventive E&","MPPolicyAttachmentInternalSourceId":8364,"PolicyAttachmentPageName":"e0fc55b8-95ac-4b53-a482-1f486d11bc56"},"5999": {"Id":5999,"MPAttachmentLetter":"A","Title":"E&M codes appended with modifier 25 should be reimbursed at 50% of the applicable fee schedule amount when submitted on the same date of service, by the same professional provider or other qualified health care provider, as a minor procedure.","MPPolicyAttachmentInternalSourceId":8365,"PolicyAttachmentPageName":"5dbe6be8-f37a-4f76-a5c3-548eb733032a"},}
3dc4cf47-3477-4eb5-b63d-0faa211d9235.aspx
  
03.00.05wModifier50:BilateralProcedure03.00.05wClinical Logic (03)Modifier 50: Bilateral Procedure3dc4cf47-3477-4eb5-b63d-0faa211d92355978Modifier 50: Bilateral Procedure03.00.05
c089bb2c-423f-4e85-8d78-7e2522acf4bf.aspx
  
03.00.32bModifier52:ReducedServices03.00.32bClinical Logic (03)Modifier 52: Reduced Servicesc089bb2c-423f-4e85-8d78-7e2522acf4bf5522Modifier 52: Reduced Services03.00.32
b835e172-8f47-42be-a0cf-3f63a7d3133d.aspx
  
03.00.33bModifier53:DiscontinuedProcedure03.00.33bClinical Logic (03)Modifier 53: Discontinued Procedureb835e172-8f47-42be-a0cf-3f63a7d3133d5523Modifier 53: Discontinued Procedure03.00.33
b5c59444-0f62-4fcb-8717-62bb24a5bbaf.aspx
  
03.00.16pModifier57:DecisionforSurgery03.00.16pClinical Logic (03)Modifier 57: Decision for Surgeryb5c59444-0f62-4fcb-8717-62bb24a5bbaf5489Modifier 57:  Decision for Surgery03.00.16
ee014007-3e1d-4bb1-995f-b82daef71632.aspx
  
00.10.11xModifier62:TwoSurgeons00.10.11xAdministrative (00)Modifier 62: Two Surgeonsee014007-3e1d-4bb1-995f-b82daef716325979Modifier 62: Two Surgeons00.10.11
cee9d4a3-ebc8-4a88-b14f-de037afbcbe6.aspx
  
00.10.17oModifier66:SurgicalTeam00.10.17oAdministrative (00)Modifier 66: Surgical Teamcee9d4a3-ebc8-4a88-b14f-de037afbcbe65980Modifier 66: Surgical Team00.10.17
{"5981": {"Id":5981,"MPAttachmentLetter":"A","Title":"Team Surgery Review Form","MPPolicyAttachmentInternalSourceId":8358,"PolicyAttachmentPageName":"24fdde6f-63ee-472b-9e9e-00fd65735f42"},}
42176633-901e-445a-8b52-c1d8653c85bf.aspx
  
03.00.02cModifier76:RepeatProcedureorServicebySamePhysicianorOtherQualifiedHealthCareProfessional03.00.02cClinical Logic (03)Modifier 76: Repeat Procedure or Service by Same Physician or Other Qualified Health Care Professional42176633-901e-445a-8b52-c1d8653c85bf5104Modifier 76: Repeat Procedure or Service by Same Physician or Other Qualified Health Care Professional03.00.02
37236b28-776f-4b06-9c4f-02834e055984.aspx
  
03.00.11cModifier77:RepeatProcedureorServicebyAnotherPhysicianorOtherQualifiedHealthCareProfessional03.00.11cClinical Logic (03)Modifier 77: Repeat Procedure or Service by Another Physician or Other Qualified Health Care Professional37236b28-776f-4b06-9c4f-02834e0559845101Modifier 77: Repeat Procedure or Service by Another Physician or Other Qualified Health Care Professional03.00.11
e6f338ca-9339-4559-a434-d115fab590e0.aspx
  
03.00.12gModifier78:UnplannedReturntotheOperating/ProcedureRoombytheSamePhysicianorOtherQualifiedHealthCareProfessionalFollowingtheInitialProcedureforaRelatedProcedureDuringthePostoperativePeriod03.00.12gClinical Logic (03)Modifier 78: Unplanned Return to the Operating/Procedure Room by the Same Physician or Other Qualified Health Care Professional Following the Initial Procedure for a Related Procedure During the Postoperative Periode6f338ca-9339-4559-a434-d115fab590e05105Modifier 78: Unplanned Return to the Operating/Procedure Room by the Same Physician or Other Qualified Health Care Professional Following the Initial Procedure for a Related Procedure During the Postoperative Period03.00.12
eda29625-d354-43e3-a2cf-888ee03cc897.aspx
  
03.00.28nModifier79:UnrelatedProcedureorServicebytheSamePhysicianorOtherQualifiedHealthCareProfessionalDuringthePostoperativePeriod03.00.28nClinical Logic (03)Modifier 79: Unrelated Procedure or Service by the Same Physician or Other Qualified Health Care Professional During the Postoperative Periodeda29625-d354-43e3-a2cf-888ee03cc8975102Modifier 79:  Unrelated Procedure or Service by the Same Physician or Other Qualified Health Care Professional During the Postoperative Period03.00.28
f41270d4-d5fa-48e5-9b0e-5770b0846324.aspx
  
03.00.20rModifiers26(ProfessionalComponent)andTC(TechnicalComponent)03.00.20rClinical Logic (03)Modifiers 26 (Professional Component) and TC (Technical Component)f41270d4-d5fa-48e5-9b0e-5770b08463245982Modifiers 26 (Professional Component) and TC (Technical Component)03.00.20
0fb889fd-6888-486f-8342-f494ae0256cf.aspx
  
00.10.18vModifiersforAssistant-at-SurgeryServices:80,81,82,andAS00.10.18vAdministrative (00)Modifiers for Assistant-at-Surgery Services: 80, 81, 82, and AS0fb889fd-6888-486f-8342-f494ae0256cf5989Modifiers for Assistant-at-Surgery Services: 80, 81, 82, and AS00.10.18
0e19258a-b273-40cc-97ad-49f9bf2c9f4c.aspx
  
03.00.31gModifiersforSplitorSharedSurgicalServices(Modifiers54,55,and56)03.00.31gClinical Logic (03)Modifiers for Split or Shared Surgical Services (Modifiers 54, 55, and 56)0e19258a-b273-40cc-97ad-49f9bf2c9f4c5520Modifiers for Split or Shared Surgical Services (Modifiers 54, 55, and 56)03.00.31
d0e4489b-c807-4e43-9abb-a90f6f1cebdd.aspx
  
03.00.08fModifiersXE,XS,XP,XU,and5903.00.08fClinical Logic (03)Modifiers XE, XS, XP, XU, and 59d0e4489b-c807-4e43-9abb-a90f6f1cebdd4018Modifiers XE, XS, XP, XU, and 5903.00.08
7c095e43-8c2f-4cc6-bde8-ff7ce5d0d066.aspx
  
08.01.52eMogamulizumab-kpkc(Poteligeo®)08.01.52ePharmacy (08)Mogamulizumab-kpkc (Poteligeo®)7c095e43-8c2f-4cc6-bde8-ff7ce5d0d0665764Mogamulizumab-kpkc (Poteligeo®)08.01.52
d2afa137-cc2f-4a14-8d24-28c4eda18252.aspx
  
11.08.23kMohsMicrographicSurgery11.08.23kSurgery (11)Mohs Micrographic Surgeryd2afa137-cc2f-4a14-8d24-28c4eda182526090Mohs Micrographic Surgery11.08.23
{"6091": {"Id":6091,"MPAttachmentLetter":"A","Title":"ICD 10 Codes","MPPolicyAttachmentInternalSourceId":8479,"PolicyAttachmentPageName":"bd0ed2ed-dab4-4dce-bab8-93180a43ff67"},}
e0a90c62-6b50-403d-bdfe-f6b6ea545afd.aspx
  
06.02.36dMolecularTestingfortheManagementofPancreaticCystsorBarrett'sEsophagus(IndependenceAdministrators)06.02.36dPathology and Laboratory (06)Molecular Testing for the Management of Pancreatic Cysts or Barrett's Esophagus (Independence Administrators)e0a90c62-6b50-403d-bdfe-f6b6ea545afd5283Molecular Testing for the Management of Pancreatic Cysts or Barrett's Esophagus (Independence Administrators)06.02.36
9100f336-6896-4fc2-bb95-b5f56f97a2bf.aspx
  
08.01.93bMonoclonalAntibodiesDirectedAgainstAmyloidfortheTreatmentofAlzheimer'sDisease08.01.93bPharmacy (08)Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease9100f336-6896-4fc2-bb95-b5f56f97a2bf5826Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease08.01.93
1c90381d-5c4e-41a7-b8a3-405061c1eadb.aspx
  
08.02.00aMosunetuzumab-axgb(Lunsumio™)08.02.00aPharmacy (08)Mosunetuzumab-axgb (Lunsumio™)1c90381d-5c4e-41a7-b8a3-405061c1eadb5424Mosunetuzumab-axgb (Lunsumio™)08.02.00
5db42656-7643-4771-b865-b073924d040a.aspx
  
08.01.53bMoxetumomabPasudotox-tdfk(Lumoxiti™)08.01.53bPharmacy (08)Moxetumomab Pasudotox-tdfk (Lumoxiti™)5db42656-7643-4771-b865-b073924d040a5344Moxetumomab Pasudotox-tdfk (Lumoxiti™)08.01.53
721d132a-c067-4496-9719-659f7dcda8ae.aspx
  
06.02.32dMultigeneExpressionAssaysforPredictingRecurrenceinColonCancer(IndependenceAdministrators)06.02.32dPathology and Laboratory (06)Multigene Expression Assays for Predicting Recurrence in Colon Cancer (Independence Administrators)721d132a-c067-4496-9719-659f7dcda8ae5821Multigene Expression Assays for Predicting Recurrence in Colon Cancer (Independence Administrators)06.02.32
1decf4ce-ff05-4578-b4ab-1846c812b195.aspx
  
00.01.60iMultipleProcedurePaymentReduction(MPPR)onCertainDiagnosticServices00.01.60iAdministrative (00)Multiple Procedure Payment Reduction (MPPR) on Certain Diagnostic Services1decf4ce-ff05-4578-b4ab-1846c812b1955875Multiple Procedure Payment Reduction (MPPR) on Certain Diagnostic Services00.01.60
{}
2b7c84a7-b153-48f2-93d2-bca3e96ac05e.aspx
  
00.01.68aMultipleProcedurePaymentReductionGuidelinesforPhysical,Occupational,andSpeechTherapyServices00.01.68aAdministrative (00)Multiple Procedure Payment Reduction Guidelines for Physical, Occupational, and Speech Therapy Services2b7c84a7-b153-48f2-93d2-bca3e96ac05e6025Multiple Procedure Payment Reduction Guidelines for Physical, Occupational, and Speech Therapy Services00.01.68
{"6026": {"Id":6026,"MPAttachmentLetter":"A","Title":"Multiple Reduction Always Therapy Procedure Codes","MPPolicyAttachmentInternalSourceId":8420,"PolicyAttachmentPageName":"45f1e7bc-6fcf-491f-83c6-c1dc267210a9"},}
afb5dab9-c104-4a32-9f0f-0165854ddf75.aspx
  
11.00.10xMultipleSurgeryPaymentReduction11.00.10xSurgery (11)Multiple Surgery Payment Reductionafb5dab9-c104-4a32-9f0f-0165854ddf754729Multiple Surgery Payment Reduction11.00.10
{"4730": {"Id":4730,"MPAttachmentLetter":"B","Title":"Healthcare Common Procedure Coding System (HCPCS) Codes To Which Multiple Surgery Payment Reduction Applies","MPPolicyAttachmentInternalSourceId":6895,"PolicyAttachmentPageName":"b6201a62-c6aa-4b34-aaaf-f2d0451c1d96"},"4731": {"Id":4731,"MPAttachmentLetter":"A2","Title":"Current Procedural Terminology (CPT) Codes To Which Multiple Surgery Payment Reduction Applies","MPPolicyAttachmentInternalSourceId":6896,"PolicyAttachmentPageName":"882d134d-14c7-4bd1-8fee-644c9ae71729"},"4732": {"Id":4732,"MPAttachmentLetter":"A1","Title":"Current Procedural Terminology (CPT) Codes To Which Multiple Surgery Payment Reduction Applies","MPPolicyAttachmentInternalSourceId":6897,"PolicyAttachmentPageName":"55e70aba-5dd9-4d91-b843-eee058d5cd6f"},}
92e75520-e862-49c3-818e-b4979eaae14d.aspx
  
00.01.66kMusculoskeletalServices(Independence)00.01.66kAdministrative (00)Musculoskeletal Services (Independence)92e75520-e862-49c3-818e-b4979eaae14d5908Musculoskeletal Services (Independence)00.01.66
{"5909": {"Id":5909,"MPAttachmentLetter":"C","Title":"Procedures Codes for Interventional Pain Management","MPPolicyAttachmentInternalSourceId":8183,"PolicyAttachmentPageName":"0df055d8-8afe-4f09-a131-3f73601c5139"},"5910": {"Id":5910,"MPAttachmentLetter":"B","Title":"Procedure Codes for Joint Surgery","MPPolicyAttachmentInternalSourceId":8185,"PolicyAttachmentPageName":"696fba3f-4c70-48f5-8441-84417ce83701"},"5911": {"Id":5911,"MPAttachmentLetter":"A","Title":"Procedure Codes for Spinal Surgery","MPPolicyAttachmentInternalSourceId":8187,"PolicyAttachmentPageName":"2881014a-4648-425f-aa27-d54c82896021"},}
4dffeac0-500f-4393-82a0-acab6a2a68b6.aspx
  
08.02.11NadofarageneFiradenovec-vncg(Adstiladrin®)08.02.11Pharmacy (08)Nadofaragene Firadenovec-vncg (Adstiladrin®)4dffeac0-500f-4393-82a0-acab6a2a68b65712Nadofaragene Firadenovec-vncg (Adstiladrin®)08.02.11
38c9d73e-1854-43a4-a84e-996a8548f43d.aspx
  
08.00.64gNatalizumab(Tysabri®)08.00.64gPharmacy (08)Natalizumab (Tysabri®)38c9d73e-1854-43a4-a84e-996a8548f43d5029Natalizumab (Tysabri®)08.00.64
f9a23570-9bcf-4c3d-b80c-800b09727c20.aspx
  
00.01.56bNationalCorrectCodingInitiative(NCCI)CodePairEdits00.01.56bAdministrative (00)National Correct Coding Initiative (NCCI) Code Pair Editsf9a23570-9bcf-4c3d-b80c-800b09727c205521National Correct Coding Initiative (NCCI) Code Pair Edits00.01.56
4f4f2c65-9768-43af-81cf-7b151317458c.aspx
  
05.00.15tNebulizersandInhalationSolutions05.00.15tDME (05)Nebulizers and Inhalation Solutions4f4f2c65-9768-43af-81cf-7b151317458c5588Nebulizers and Inhalation Solutions05.00.15
49d423dc-c100-4119-96c9-325d9c3971db.aspx
  
05.00.38mNegativePressureWoundTherapySystems05.00.38mDME (05)Negative Pressure Wound Therapy Systems49d423dc-c100-4119-96c9-325d9c3971db5779Negative Pressure Wound Therapy Systems05.00.38
4737bfc4-8151-4650-b879-626391add39c.aspx
  
07.03.18tNerveConductionStudies(NCS)andRelatedElectrodiagnosticStudies07.03.18tMedicine (07)Nerve Conduction Studies (NCS) and Related Electrodiagnostic Studies4737bfc4-8151-4650-b879-626391add39c5735Nerve Conduction Studies (NCS) and Related Electrodiagnostic Studies07.03.18
{"5736": {"Id":5736,"MPAttachmentLetter":"A","Title":"Recommended Guidelines for Electrodiagnostic Studies","MPPolicyAttachmentInternalSourceId":7813,"PolicyAttachmentPageName":"c208367d-6985-4462-8fc3-ec44e9f51f1a"},"5737": {"Id":5737,"MPAttachmentLetter":"F","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":7814,"PolicyAttachmentPageName":"226c503b-cf58-4267-9763-0cbc87efdc57"},"5738": {"Id":5738,"MPAttachmentLetter":"C","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":7815,"PolicyAttachmentPageName":"07ff8a68-0f8c-408a-9664-3631f23f9c84"},"5739": {"Id":5739,"MPAttachmentLetter":"D","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":7816,"PolicyAttachmentPageName":"6d5832bb-72f0-4b05-b20b-00786afdd307"},"5740": {"Id":5740,"MPAttachmentLetter":"K","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":7817,"PolicyAttachmentPageName":"e159685b-a386-4363-967a-1a3cca44f562"},"5741": {"Id":5741,"MPAttachmentLetter":"E","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":7818,"PolicyAttachmentPageName":"f2eca517-080a-45b8-adc0-dd4e2c41b5ed"},"5742": {"Id":5742,"MPAttachmentLetter":"G","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":7819,"PolicyAttachmentPageName":"d1d18385-d8a9-497b-a5c9-6c35184bda56"},"5743": {"Id":5743,"MPAttachmentLetter":"J","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":7820,"PolicyAttachmentPageName":"a22a7017-1c50-44b1-90d9-b6f5b88919b2"},"5744": {"Id":5744,"MPAttachmentLetter":"H","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":7821,"PolicyAttachmentPageName":"f255d926-646a-47fe-a587-c7756bc6d023"},"5745": {"Id":5745,"MPAttachmentLetter":"I","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":7822,"PolicyAttachmentPageName":"06678359-14ee-4548-a49e-187d2e879eb0"},"5746": {"Id":5746,"MPAttachmentLetter":"B","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":7823,"PolicyAttachmentPageName":"d1f85fbc-f249-49c4-9426-a117b4ca95c8"},}
04c283f0-0d21-49f7-b081-f6509c7cf356.aspx
  
06.02.38dNerveFiberDensityTesting06.02.38dPathology and Laboratory (06)Nerve Fiber Density Testing04c283f0-0d21-49f7-b081-f6509c7cf3565028Nerve Fiber Density Testing06.02.38
9e05fb40-63e9-45e2-91c3-74caff5be60b.aspx
  
05.00.73gNeuromuscularElectricalStimulators(NMES)andFunctionalElectricalStimulators(FES)05.00.73gDME (05)Neuromuscular Electrical Stimulators (NMES) and Functional Electrical Stimulators (FES)9e05fb40-63e9-45e2-91c3-74caff5be60b5459Neuromuscular Electrical Stimulators (NMES) and Functional Electrical Stimulators (FES)05.00.73
d6821fc1-495d-449a-bff1-98b30acc79a0.aspx
  
07.03.08nNeuropsychologicalTestingforNeurologicallyBasedConditions07.03.08nMedicine (07)Neuropsychological Testing for Neurologically Based Conditionsd6821fc1-495d-449a-bff1-98b30acc79a05635Neuropsychological Testing for Neurologically Based Conditions07.03.08
{"5636": {"Id":5636,"MPAttachmentLetter":"A","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":7751,"PolicyAttachmentPageName":"86db0f59-e480-40e7-bde9-ec918a188744"},}
9a0b90c8-7404-4c27-9a2c-836963f214ef.aspx
  
00.01.44jNeverEventsandPreventableSeriousAdverseEvents00.01.44jAdministrative (00)Never Events and Preventable Serious Adverse Events9a0b90c8-7404-4c27-9a2c-836963f214ef4859Never Events and Preventable Serious Adverse Events00.01.44
{"4860": {"Id":4860,"MPAttachmentLetter":"C","Title":"Never Event or Preventable Serious Adverse Event Reporting Form","MPPolicyAttachmentInternalSourceId":6832,"PolicyAttachmentPageName":"400c99ce-1404-4084-af26-46afcc087cd2"},"4861": {"Id":4861,"MPAttachmentLetter":"B","Title":"New Jersey Act No. 2471","MPPolicyAttachmentInternalSourceId":6833,"PolicyAttachmentPageName":"b1ac50ac-b757-4e84-b1d3-db6d4e012156"},"4862": {"Id":4862,"MPAttachmentLetter":"A","Title":"Pennsylvania House Bill No. 84 addressing Never Events and Preventable Serious Adverse Events","MPPolicyAttachmentInternalSourceId":6834,"PolicyAttachmentPageName":"c3b9bfb0-da02-4bfe-a8a1-a34b4e45db8e"},}
5c4684df-177c-42b5-8552-8e47388b798f.aspx
  
08.01.62cNivolumab(Opdivo®)08.01.62cPharmacy (08)Nivolumab (Opdivo®)5c4684df-177c-42b5-8552-8e47388b798f5987Nivolumab (Opdivo®)08.01.62
{"5988": {"Id":5988,"MPAttachmentLetter":"A","Title":"ICD-10 Codes and Narratives","MPPolicyAttachmentInternalSourceId":8074,"PolicyAttachmentPageName":"5e97c8fc-54cc-4499-9d0a-f34d9ab451e6"},}
4b656b5a-1933-4c05-a6e1-3c0d2797d402.aspx
  
08.01.94bnivolumabandrelatlimab-rmbw(Opdualag™)08.01.94bPharmacy (08)nivolumab and relatlimab-rmbw (Opdualag™) 4b656b5a-1933-4c05-a6e1-3c0d2797d4025079nivolumab and relatlimab-rmbw (Opdualag™) 08.01.94
f7225caa-a769-4de3-9572-de413c1fdd2f.aspx
  
07.10.05nNoncontraceptiveUseoftheLevonorgestrel-ReleasingIntrauterineSystem07.10.05nMedicine (07)Noncontraceptive Use of the Levonorgestrel-Releasing Intrauterine Systemf7225caa-a769-4de3-9572-de413c1fdd2f5991Noncontraceptive Use of the Levonorgestrel-Releasing Intrauterine System07.10.05
33583433-bcce-4f0e-9195-bc63df104ee3.aspx
  
07.03.25aNonemergentInpatientVideoElectroencephalogram(EEG)MonitoringandAmbulatoryEEGMonitoringintheHome07.03.25aMedicine (07)Nonemergent Inpatient Video Electroencephalogram (EEG) Monitoring and Ambulatory EEG Monitoring in the Home33583433-bcce-4f0e-9195-bc63df104ee35110Nonemergent Inpatient Video Electroencephalogram (EEG) Monitoring and Ambulatory EEG Monitoring in the Home07.03.25
0ad70f90-df9d-4ed5-a24a-a1a8029ee4e3.aspx
  
06.02.47eNoninvasivePrenatalScreeningforFetalAneuploidiesUsingCell-FreeFetalDNA(IndependenceAdministrators)06.02.47ePathology and Laboratory (06)Noninvasive Prenatal Screening for Fetal Aneuploidies Using Cell-Free Fetal DNA (Independence Administrators)0ad70f90-df9d-4ed5-a24a-a1a8029ee4e36058Noninvasive Prenatal Screening for Fetal Aneuploidies Using Cell-Free Fetal DNA (Independence Administrators)06.02.47
66dfdaab-e8c1-46c1-b52f-5e6dcdc2d5b6.aspx
  
05.00.30pNoninvasiveRespiratoryAssistDevices(RADs):ContinuousPositiveAirwayPressure(CPAP)Devices,Auto-AdjustingPositiveAirwayPressure(A​PAP)andBi-LevelDevices05.00.30pDME (05)Noninvasive Respiratory Assist Devices (RADs): Continuous Positive Airway Pressure (CPAP) Devices, Auto-Adjusting Positive Airway Pressure (A​PAP) and Bi-Level Devices66dfdaab-e8c1-46c1-b52f-5e6dcdc2d5b65590Noninvasive Respiratory Assist Devices (RADs): Continuous Positive Airway Pressure (CPAP) Devices, Auto-Adjusting Positive Airway Pressure (A​PAP) and Bi-Level Devices05.00.30
328cff1c-bab1-4db6-a65d-208aab0e9a6e.aspx
  
06.02.56hNoninvasiveTechniquesfortheEvaluationandMonitoringofIndividualswithChronicLiverDisease06.02.56hPathology and Laboratory (06)Noninvasive Techniques for the Evaluation and Monitoring of Individuals with Chronic Liver Disease328cff1c-bab1-4db6-a65d-208aab0e9a6e5923Noninvasive Techniques for the Evaluation and Monitoring of Individuals with Chronic Liver Disease06.02.56
b02f004a-3f5f-49af-aff7-4c1f6299e9f1.aspx
  
07.08.01fNon-SurgicalSpinalDecompressionTherapy07.08.01fMedicine (07)Non-Surgical Spinal Decompression Therapyb02f004a-3f5f-49af-aff7-4c1f6299e9f16076Non-Surgical Spinal Decompression Therapy07.08.01
ea1066ee-6337-40a1-8848-516c44b36058.aspx
  
00.01.24jNotMedicallyNecessaryServicesandObsoleteorUnreliableDiagnosticTests00.01.24jAdministrative (00)Not Medically Necessary Services and Obsolete or Unreliable Diagnostic Testsea1066ee-6337-40a1-8848-516c44b360585435Not Medically Necessary Services and Obsolete or Unreliable Diagnostic Tests00.01.24
791c320a-6657-46fd-9c81-6b7a599c6b6e.aspx
  
11.15.19eNucleoplasty11.15.19eSurgery (11)Nucleoplasty791c320a-6657-46fd-9c81-6b7a599c6b6e5258Nucleoplasty11.15.19
12e551b1-d2a2-4509-8a41-d9084930dbb2.aspx
  
08.00.18pNutritionalFormulas,EnteralNutrition,MedicalFoods,Low-ProteinModifiedFoodProducts,andDonatedBreastMilk08.00.18pPharmacy (08)Nutritional Formulas, Enteral Nutrition, Medical Foods, Low-Protein Modified Food Products, and Donated Breast Milk12e551b1-d2a2-4509-8a41-d9084930dbb25646Nutritional Formulas, Enteral Nutrition, Medical Foods, Low-Protein Modified Food Products, and Donated Breast Milk08.00.18
{"5647": {"Id":5647,"MPAttachmentLetter":"A","Title":"PA Mandates","MPPolicyAttachmentInternalSourceId":7680,"PolicyAttachmentPageName":"4f8411b5-b08a-44b2-8cce-4ccb8367463b"},"5648": {"Id":5648,"MPAttachmentLetter":"C","Title":"Caloric Requirements","MPPolicyAttachmentInternalSourceId":7681,"PolicyAttachmentPageName":"4aa4984d-5169-445e-a413-b6de00a28703"},"5649": {"Id":5649,"MPAttachmentLetter":"B","Title":"NJ Mandates","MPPolicyAttachmentInternalSourceId":7682,"PolicyAttachmentPageName":"58eecbb8-38a3-4002-a197-cc14f27bebe1"},}
7f8302c2-19f4-4ddb-8f99-4a0bfa735caf.aspx
  
00.03.10FObstetricalUltrasoundsforMembersEnrolledinaHealthMaintenanceOrganization(HMO)orHealthMaintenanceOrganizationPoint-of-Service(HMO-POS)Product00.03.10FAdministrative (00)Obstetrical Ultrasounds for Members Enrolled in a Health Maintenance Organization (HMO) or Health Maintenance Organization Point-of-Service (HMO-POS) Product7f8302c2-19f4-4ddb-8f99-4a0bfa735caf5560Obstetrical Ultrasounds for Members Enrolled in a Health Maintenance Organization (HMO) or Health Maintenance Organization Point-of-Service (HMO-POS) Product00.03.10
{"5561": {"Id":5561,"MPAttachmentLetter":"B","Title":"Rule out Ectopic Pregnancy","MPPolicyAttachmentInternalSourceId":7548,"PolicyAttachmentPageName":"93506959-7870-42f1-aab0-85b9aa8f67dd"},"5562": {"Id":5562,"MPAttachmentLetter":"C","Title":"Rule out intrauterine pathology and Screening for Fetal abnormalities","MPPolicyAttachmentInternalSourceId":7549,"PolicyAttachmentPageName":"b1e7dbb7-62be-499f-a75c-1852e92dae11"},"5563": {"Id":5563,"MPAttachmentLetter":"A","Title":"High Risk Pregnancy","MPPolicyAttachmentInternalSourceId":7550,"PolicyAttachmentPageName":"79c5e79c-da07-4d3f-a0c8-3cdef56fd0dd"},"5564": {"Id":5564,"MPAttachmentLetter":"D","Title":"First-trimester screening and Ovarian Dysfunction","MPPolicyAttachmentInternalSourceId":7551,"PolicyAttachmentPageName":"e83b73f7-1ee4-4c48-a27a-5307de6ba5af"},}
ae1aeee4-6171-4fdd-8df9-4446b77289ad.aspx
  
08.01.38cOcrelizumab(Ocrevus®)08.01.38cPharmacy (08)Ocrelizumab (Ocrevus®)ae1aeee4-6171-4fdd-8df9-4446b77289ad5226Ocrelizumab (Ocrevus®)08.01.38
4c196624-4864-4bb7-8aef-306caa06aa05.aspx
  
08.01.10hOctreotideAcetate(Sandostatin®LARDepot)08.01.10hPharmacy (08)Octreotide Acetate (Sandostatin® LAR Depot)4c196624-4864-4bb7-8aef-306caa06aa055508Octreotide Acetate (Sandostatin® LAR Depot)08.01.10
{"5509": {"Id":5509,"MPAttachmentLetter":"A","Title":"ICD-10 CODES AND NARRATIVES","MPPolicyAttachmentInternalSourceId":7469,"PolicyAttachmentPageName":"27cb9574-e31d-4db2-b515-bdb36eabd04e"},}
bb8577e0-65a6-4cae-b2ba-f2fd1e235004.aspx
  
08.00.15fOff-labelCoverageforPrescriptionDrugsand/orBiologics08.00.15fPharmacy (08)Off-label Coverage for Prescription Drugs and/or Biologicsbb8577e0-65a6-4cae-b2ba-f2fd1e2350045109Off-label Coverage for Prescription Drugs and/or Biologics08.00.15
82766385-cc7c-4d38-92a3-60d3a64891cc.aspx
  
08.01.96aolipudasealfa-rpcp(Xenpozyme™)08.01.96aPharmacy (08)olipudase alfa-rpcp (Xenpozyme™)82766385-cc7c-4d38-92a3-60d3a64891cc6020olipudase alfa-rpcp (Xenpozyme™)08.01.96
{"6021": {"Id":6021,"MPAttachmentLetter":"A","Title":"Dosing and Frequency Requirements for olipudase alfa-rpcp (Xenpozyme)","MPPolicyAttachmentInternalSourceId":8307,"PolicyAttachmentPageName":"0625ef2b-5709-4de4-b2c2-29b854d42dfd"},}
4eabb425-1607-418b-9b7e-784459bfb75d.aspx
  
08.00.55jOmalizumab(Xolair®)08.00.55jPharmacy (08)Omalizumab (Xolair®)4eabb425-1607-418b-9b7e-784459bfb75d6101Omalizumab (Xolair®)08.00.55
{"6102": {"Id":6102,"MPAttachmentLetter":"A","Title":"Dosing and Frequency Requirements for Omalizumab (Xolair®)","MPPolicyAttachmentInternalSourceId":8205,"PolicyAttachmentPageName":"a110cfad-c638-4da1-abd1-a3d188ab7d5a"},}
6805c0ac-0631-4eb5-9b58-51b0b72e4c6a.aspx
  
11.14.08dOrthognathicSurgery11.14.08dSurgery (11)Orthognathic Surgery6805c0ac-0631-4eb5-9b58-51b0b72e4c6a6055Orthognathic Surgery11.14.08
628dcdf2-33a8-45ba-a02e-0e112f82b75c.aspx
  
07.13.01jOrthoptic/PleopticTraining07.13.01jMedicine (07)Orthoptic/Pleoptic Training628dcdf2-33a8-45ba-a02e-0e112f82b75c5383Orthoptic/Pleoptic Training07.13.01
a15b2285-73dc-4a44-b463-26b1270bf485.aspx
  
11.14.12fOsteochondralAllograftTransplantation(IndependenceAdministrators)11.14.12fSurgery (11)Osteochondral Allograft Transplantation (Independence Administrators)a15b2285-73dc-4a44-b463-26b1270bf4855166Osteochondral Allograft Transplantation (Independence Administrators)11.14.12
16c02493-eb9f-49fb-a1a7-7f82484d7036.aspx
  
11.14.09hOsteochondralAutograftTransplantation(IndependenceAdministrators)11.14.09hSurgery (11)Osteochondral Autograft Transplantation (Independence Administrators)16c02493-eb9f-49fb-a1a7-7f82484d70365168Osteochondral Autograft Transplantation (Independence Administrators)11.14.09
f7b595de-89ea-47a6-af78-e12eadf82ee0.aspx
  
05.00.81OsteogenicStimulators(non-invasive,invasive/semi-invasive,electricalandultrasound)05.00.81DME (05)Osteogenic Stimulators (non-invasive, invasive/semi-invasive, electrical and ultrasound)f7b595de-89ea-47a6-af78-e12eadf82ee05451Osteogenic Stimulators (non-invasive, invasive/semi-invasive, electrical and ultrasound)05.00.81
ad7874c1-5b87-422a-8e18-dfd6233a4f02.aspx
  
05.00.50oOstomySupplies05.00.50oDME (05)Ostomy Suppliesad7874c1-5b87-422a-8e18-dfd6233a4f025403Ostomy Supplies05.00.50
{"5404": {"Id":5404,"MPAttachmentLetter":"A","Title":"HCPCS Codes for Ostomy Supplies","MPPolicyAttachmentInternalSourceId":7436,"PolicyAttachmentPageName":"8f03d7bc-9d10-46d4-8b5a-48999e039382"},}
31ca67f6-441d-4bc7-b0bd-9b509be52a5f.aspx
  
11.01.01jOtoplastyorNon-SurgicalExternalEarMolding11.01.01jSurgery (11)Otoplasty or Non-Surgical External Ear Molding31ca67f6-441d-4bc7-b0bd-9b509be52a5f5049Otoplasty or Non-Surgical External Ear Molding11.01.01
14e4a1df-d766-40d5-b280-eace3f7f69d1.aspx
  
12.05.01jOutpatientDiabetesEducationandSelf-ManagementTraining12.05.01jMiscellaneous (12)Outpatient Diabetes Education and Self-Management Training14e4a1df-d766-40d5-b280-eace3f7f69d12625Outpatient Diabetes Education and Self-Management Training12.05.01
{"2626": {"Id":2626,"MPAttachmentLetter":"A","Title":"ICD-10 CM Codes Eligible to be Reported for Outpatient Diabetes Education and Self-Management Training (E08.00- E10.3491)","MPPolicyAttachmentInternalSourceId":2371,"PolicyAttachmentPageName":"ed035dfc-85f7-4a19-b93a-5a68d1226e03"},"2627": {"Id":2627,"MPAttachmentLetter":"B","Title":"ICD-10 CM Codes Eligible to be Reported for Outpatient Diabetes Education and Self-Management Training (E10.3492- E13.37X2), Continued","MPPolicyAttachmentInternalSourceId":2372,"PolicyAttachmentPageName":"bd6c3245-6e36-47c4-b728-9b5efac2262f"},"2628": {"Id":2628,"MPAttachmentLetter":"C","Title":"ICD-10 CM Codes Eligible to be Reported for Outpatient Diabetes Education and Self-Management Training (E13.37X3- P70.2), Continued","MPPolicyAttachmentInternalSourceId":2373,"PolicyAttachmentPageName":"a903e29d-10c8-4b14-a150-f61bffb56003"},}
5cb7351b-c0f6-4bf6-a9a8-3109571bd6fb.aspx
  
10.03.01oOutpatientPhysicalMedicine,Rehabilitation,andHabilitationServices10.03.01oRehabilitation Services (10)Outpatient Physical Medicine, Rehabilitation, and Habilitation Services5cb7351b-c0f6-4bf6-a9a8-3109571bd6fb6012Outpatient Physical Medicine, Rehabilitation, and Habilitation Services10.03.01
723a7d76-536e-4781-b75b-5d23704d4fb7.aspx
  
00.03.03iOutpatientShort-TermRehabilitationServicesIncludedinCapitation00.03.03iAdministrative (00)Outpatient Short-Term Rehabilitation Services Included in Capitation723a7d76-536e-4781-b75b-5d23704d4fb75576Outpatient Short-Term Rehabilitation Services Included in Capitation00.03.03
{"5577": {"Id":5577,"MPAttachmentLetter":"A","Title":"No Title","MPPolicyAttachmentInternalSourceId":7603,"PolicyAttachmentPageName":"e3568853-d080-4f2e-ad60-2cc28a1b9be4"},}
68419e99-bc86-4c81-9fc7-c1a8c5c2c367.aspx
  
11.06.07dOvarianandInternalIliacVeinEmbolizationasTreatmentforPelvicCongestionSyndrome11.06.07dSurgery (11)Ovarian and Internal Iliac Vein Embolization as Treatment for Pelvic Congestion Syndrome68419e99-bc86-4c81-9fc7-c1a8c5c2c3675720Ovarian and Internal Iliac Vein Embolization as Treatment for Pelvic Congestion Syndrome11.06.07
798d70cf-a484-4f7d-9746-2f47f093598d.aspx
  
08.00.90pPaclitaxelProtein-BoundParticlesforInjectableSuspension(Albumin-Bound)/(Abraxane®forInjectableSuspension)08.00.90pPharmacy (08)Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound)/(Abraxane® for Injectable Suspension)798d70cf-a484-4f7d-9746-2f47f093598d5884Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound)/(Abraxane® for Injectable Suspension)08.00.90
{"5885": {"Id":5885,"MPAttachmentLetter":"A","Title":"ICD-10 codes","MPPolicyAttachmentInternalSourceId":8210,"PolicyAttachmentPageName":"0ae70eb3-3ee2-459b-8ea4-fe30d6601e16"},}
94789e05-448a-4e25-89cc-1743bf6a2010.aspx
  
07.03.27PainManagementofPeripheralNervesbyInjection07.03.27Medicine (07)Pain Management of Peripheral Nerves by Injection94789e05-448a-4e25-89cc-1743bf6a20105090Pain Management of Peripheral Nerves by Injection07.03.27
39568f1b-da2d-4cf7-be38-eece3020bcd5.aspx
  
08.00.22qPalivizumab(Synagis)08.00.22qPharmacy (08)Palivizumab (Synagis)39568f1b-da2d-4cf7-be38-eece3020bcd55575Palivizumab (Synagis)08.00.22
6cab2bf4-56db-4b38-a0ea-b28bcd932878.aspx
  
11.08.06jPanniculectomy,Abdominoplasty,AbdominalLipectomy,andOtherExcisionsofRedundantSkin11.08.06jSurgery (11)Panniculectomy, Abdominoplasty, Abdominal Lipectomy, and Other Excisions of Redundant Skin6cab2bf4-56db-4b38-a0ea-b28bcd9328785254Panniculectomy, Abdominoplasty, Abdominal Lipectomy, and Other Excisions of Redundant Skin11.08.06
{"5255": {"Id":5255,"MPAttachmentLetter":"A","Title":"ICD-10 codes","MPPolicyAttachmentInternalSourceId":7380,"PolicyAttachmentPageName":"3e6d76c6-7600-4f34-a86c-6dc44d3b4847"},}
582d2285-78e9-457a-b550-bc60892decec.aspx
  
07.10.04cParenterallyAdministeredTerbutalineSulfateforthePreventionorTreatmentofPre-TermLabor07.10.04cMedicine (07)Parenterally Administered Terbutaline Sulfate for the Prevention or Treatment of Pre-Term Labor582d2285-78e9-457a-b550-bc60892decec6113Parenterally Administered Terbutaline Sulfate for the Prevention or Treatment of Pre-Term Labor07.10.04
7e6b1434-60a9-428f-9f5d-72af4318a332.aspx
  
07.13.08ePartialCoherenceInterferometry07.13.08eMedicine (07)Partial Coherence Interferometry7e6b1434-60a9-428f-9f5d-72af4318a3325067Partial Coherence Interferometry07.13.08
{"5068": {"Id":5068,"MPAttachmentLetter":"A","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":7218,"PolicyAttachmentPageName":"3246dbfc-62a2-4a7e-9892-e3a705b06be2"},}
Previous201 - 300Next